Centessa Pharmaceuticals’ (CNTA) Buy Rating Reiterated at Guggenheim

Centessa Pharmaceuticals (NASDAQ:CNTA)‘s stock had its “buy” rating reiterated by stock analysts at Guggenheim in a report issued on Wednesday,Benzinga reports. They presently have a $28.00 price target on the stock. Guggenheim’s price objective indicates a potential upside of 87.54% from the stock’s previous close.

CNTA has been the topic of several other research reports. TD Cowen initiated coverage on shares of Centessa Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating on the stock. Morgan Stanley reaffirmed an “overweight” rating and set a $27.00 price objective on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $26.00.

Centessa Pharmaceuticals Stock Down 5.6 %

Shares of NASDAQ:CNTA traded down $0.88 during trading on Wednesday, hitting $14.93. The company’s stock had a trading volume of 155,097 shares, compared to its average volume of 527,967. Centessa Pharmaceuticals has a fifty-two week low of $7.75 and a fifty-two week high of $19.09. The business has a 50 day moving average price of $16.51 and a two-hundred day moving average price of $16.43. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. The company has a market capitalization of $1.97 billion, a PE ratio of -9.71 and a beta of 1.54.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its earnings results on Monday, March 24th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.04. As a group, research analysts expect that Centessa Pharmaceuticals will post -1.6 EPS for the current fiscal year.

Insider Transactions at Centessa Pharmaceuticals

In related news, insider Gregory M. Weinhoff sold 10,000 shares of Centessa Pharmaceuticals stock in a transaction on Thursday, December 26th. The stock was sold at an average price of $17.04, for a total transaction of $170,400.00. Following the completion of the transaction, the insider now directly owns 183,266 shares of the company’s stock, valued at approximately $3,122,852.64. The trade was a 5.17 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Saurabh Saha sold 55,000 shares of the company’s stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $16.69, for a total value of $917,950.00. Following the completion of the sale, the chief executive officer now directly owns 276,017 shares in the company, valued at $4,606,723.73. This trade represents a 16.62 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 260,168 shares of company stock worth $4,316,568. Company insiders own 11.59% of the company’s stock.

Institutional Investors Weigh In On Centessa Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC lifted its holdings in shares of Centessa Pharmaceuticals by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 57,257 shares of the company’s stock valued at $959,000 after purchasing an additional 660 shares in the last quarter. GAMMA Investing LLC raised its stake in Centessa Pharmaceuticals by 29.1% in the 4th quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock valued at $64,000 after purchasing an additional 865 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in Centessa Pharmaceuticals in the 4th quarter valued at about $31,000. Barclays PLC boosted its stake in shares of Centessa Pharmaceuticals by 1,414.9% during the 4th quarter. Barclays PLC now owns 5,302 shares of the company’s stock worth $89,000 after purchasing an additional 4,952 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Centessa Pharmaceuticals by 39.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company’s stock worth $317,000 after buying an additional 5,316 shares in the last quarter. 82.01% of the stock is owned by institutional investors and hedge funds.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.